침습성 폐렴구균 질환 : 시장 인사이트, 역학 및 예측(2036년)

Invasive Pneumococcal Disease (IPD) Insights and Trends

• The invasive pneumococcal disease market is witnessing strong growth across the leading markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, during the study period, driven by the increasing burden of pneumococcal infections, expanding vaccination coverage, and the uptake of higher-valent pneumococcal vaccines.
• A significant proportion of the IPD burden is associated with older adults, young children, and individuals with chronic or immunocompromising conditions, highlighting the need for broader vaccination coverage and targeted preventive strategies to reduce severe disease, complications, and mortality.
• The prevention of IPD primarily relies on pneumococcal vaccination strategies, including higher-valent conjugate vaccines such as PCV20 and PCV21, as well as established vaccines like PCV13 and PCV15, which provide broader serotype coverage and help reduce invasive infections, disease burden, and related complications, particularly among older adults and other high-risk populations.
• In the IPD market across the 7MM, PCV20 (PREVNAR 20/APEXXNAR) has the largest share among available pneumococcal vaccines, driven by its broad serotype coverage, strong physician adoption, and widespread implementation in adult immunization programs.
• Various surveillance systems and serotype-monitoring programs for IPD, including the Active Bacterial Core surveillance (ABCs) (US), European Centre for Disease Prevention and Control (ECDC) surveillance networks (Europe), and national pneumococcal surveillance programs in Japan, support the tracking of disease incidence, serotype distribution, vaccine effectiveness, and antimicrobial resistance patterns. These systems help guide vaccination policies, assess public health impact, and inform region-specific prevention strategies.
• The emerging IPD pipeline is relatively limited and primarily focused on next-generation higher-valent vaccines designed to expand serotype coverage and address residual disease burden. Key candidates include SP0202, developed by Sanofi and SK Bioscience; PF-07872412 (25vPnC), developed by Pfizer; and GSK5459248, developed by GSK, all of which are being evaluated to strengthen pneumococcal disease prevention strategies further.

DelveInsight's 'Invasive Pneumococcal Disease (IPD)- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the IPD, historical and forecasted epidemiology, as well as the IPD market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The IPD market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates IPD patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in IPD and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Invasive Pneumococcal Disease (IPD) Market

Rising Invasive Pneumococcal Disease (IPD) Incidence

The increasing incidence of IPD, particularly among males, is a primary driver of IPD market expansion, supported by the rising burden of pneumococcal infections among older adults, immunocompromised individuals, and patients with chronic comorbidities, which continues to increase demand for effective vaccination and preventive strategies.

Rising Opportunities in Advanced Pneumococcal Vaccine Development

The growing burden of IPD and the emergence of pneumococcal serotypes are creating opportunities to develop broader-coverage vaccines to enhance disease prevention and reduce infection rates in high-risk populations.

Emerging Invasive Pneumococcal Disease (IPD) Competitive Landscape

The IPD landscape is advancing with the development of next-generation pneumococcal vaccines. Key emerging therapies include SP0202 (Sanofi/SK Bioscience), PF-07872412 (25vPnC) (Pfizer), and GSK5459248 (GSK), which aim to expand serotype coverage and improve protection against invasive pneumococcal disease.

Invasive Pneumococcal Disease (IPD) Understanding and Treatment Algorithm

Invasive Pneumococcal Disease (IPD) Overview and Diagnosis

IPD is a severe bacterial infection caused by Streptococcus pneumoniae in which the bacteria invade normally sterile body sites such as the blood, cerebrospinal fluid, or lungs, leading to serious complications and high morbidity and mortality. Common manifestations include bacteremia, meningitis, and bacteremic pneumonia, often occurring in young children, older adults, and immunocompromised individuals, with risk factors including chronic diseases, weakened immunity, smoking, and inadequate vaccination coverage.

IPD is diagnosed through clinical evaluation, microbiological testing, and identification of Streptococcus pneumoniae from normally sterile body sites such as blood or cerebrospinal fluid. Diagnostic workup includes blood cultures, cerebrospinal fluid analysis, PCR assays, urinary antigen tests, CBC, inflammatory markers, and imaging studies to assess infection severity and complications, while disease progression and patient risk are evaluated based on clinical presentation and underlying comorbidities.

Invasive Pneumococcal Disease (IPD) Treatment

The primary goals of IPD treatment are rapid eradication of Streptococcus pneumoniae, control of systemic infection, and prevention of complications such as sepsis and meningitis. Management relies on prompt empiric antibiotics (e.g., ceftriaxone, cefotaxime, vancomycin in severe cases), followed by targeted therapy based on culture results. Adjunctive corticosteroids may be used in meningitis to reduce inflammatory injury, while supportive ICU care (oxygen, fluids, vasopressors) is essential in severe disease. Vaccination remains the key preventive strategy to reduce IPD incidence in high-risk populations.

Invasive Pneumococcal Disease (IPD) Unmet Needs

The section "unmet needs of Invasive Pneumococcal Disease (IPD)" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Delayed diagnosis and rapid disease progression lead to high morbidity and mortality

2. Increasing antimicrobial resistance limiting treatment effectiveness

3. Incomplete protection against emerging pneumococcal serotypes

4. Low vaccination coverage in high-risk and elderly populations, and others.....

Invasive Pneumococcal Disease (IPD) Epidemiology

Key Findings from Invasive Pneumococcal Disease (IPD) Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the incident cases of IPD are expected to increase during the forecast period due to factors such as population aging, increased antibiotic resistance, evolving bacterial strains, and potential gaps in vaccination coverage.
• Age-specific rates for IPD were highest among adults aged 65 years or older, likely due to age-related decline in immune function and comorbidities.
• IPD cases were slightly more common in males compared with females. This difference may be attributed to higher exposure to risk factors such as smoking, alcohol use, occupational exposure, and a greater prevalence of chronic underlying conditions in males, which can increase susceptibility to pneumococcal infection.
• The treatable cases of IPD are expected to increase in the US, owing to the introduction of new and emerging therapies.

Invasive Pneumococcal Disease (IPD) Drug Chapters & Competitive Analysis

The IPD drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the IPD treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the IPD therapeutics market.

Approved Therapies for Invasive Pneumococcal Disease (IPD)

PCV20 (PREVNAR/APEXXNAR): Pfizer

PCV20 by Pfizer is a 20-valent pneumococcal conjugate vaccine administered by intramuscular injection to prevent IPD and pneumococcal pneumonia. The vaccine induces serotype-specific opsonising antibodies against 20 Streptococcus pneumoniae serotypes by conjugation to the CRM197 carrier protein. PCV20 first received FDA approval in 2021 and was later approved in 2023 for the prevention of IPD in infants and children aged six weeks through 17 years, as well as otitis media in younger children. The FDA also granted PREVNAR 20 Breakthrough Therapy Designation in August 2020 for the pediatric IPD indication. In February 2022, the EMA approved PCV20 for use in the European Union under the brand name APEXXNAR. The vaccine expands on PREVNAR 13 by including seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) associated with antibiotic resistance, increased disease severity, and invasive potential, which collectively accounted for an estimated 37% of IPD cases in US children under five years of age. PCV20 is primarily used as a preventive vaccination strategy in pediatric and adult populations at risk of pneumococcal infections.

PCV21 (CAPVAXIVE): Merck

PCV21, developed by Merck, is a 21-valent pneumococcal conjugate vaccine approved for active immunization against IPD and pneumococcal pneumonia in adults aged 18 years and older. Administered as a single intramuscular dose, CAPVAXIVE works by inducing serotype-specific opsonophagocytic antibody responses against 21 Streptococcus pneumoniae serotypes (3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B), including eight unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) not covered by other approved pneumococcal vaccines. The vaccine is specifically designed to target serotypes predominantly responsible for adult IPD and has demonstrated broader serotype coverage compared to PCV20, covering approximately 84-85% of IPD cases in adults aged 50 years and older based on CDC epidemiological data. CAPVAXIVE received its first FDA approval in 2024 and is positioned as a preventive first-line vaccination strategy for adults at risk of pneumococcal disease.

Invasive Pneumococcal Disease (IPD) Pipeline Analysis

SP0202: Sanofi/SK Bioscience

SP0202, developed by Sanofi and SK Bioscience, is an investigational PCV designed to prevent pneumococcal diseases, including IPD, caused by multiple Streptococcus pneumoniae serotypes. The vaccine works by inducing serotype-specific immune responses through conjugation technology, generating functional antibodies that protect against pneumococcal infection and invasive disease. SP0202 is being evaluated in pediatric populations, including infants and toddlers, to offer broad serotype coverage, durable immune protection, and a favorable safety profile.

PF-07872412 (25vPnC): Pfizer

PF-07872412 (25vPnC), developed by Pfizer, is an investigational 25-valent pneumococcal conjugate vaccine designed to provide broad protection against IPD and other pneumococcal infections. The vaccine works by inducing serotype-specific immune responses against 25 Streptococcus pneumoniae serotypes, including those associated with significant residual disease burden. By expanding serotype coverage beyond currently available pneumococcal conjugate vaccines, PF-07872412 aims to enhance protection against pneumococcal disease while maintaining a favorable safety and immunogenicity profile.

Invasive Pneumococcal Disease (IPD) Key Players, Market Leaders and Emerging Companies

• Pfizer
• Merck
• Sanofi
• SK Bioscience
• GSK, and others

Invasive Pneumococcal Disease (IPD) Drug Updates

• In May 2026, Pfizer reported positive Phase II results for its 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC) in infants. The study evaluated a four-dose regimen against PREVNAR 20 and demonstrated favorable safety, tolerability, and immunogenicity. Notably, 25vPnC generated 8.8-fold higher geometric mean antibody titers against serotype 3 compared with PREVNAR 20 one month after the third dose.
• In September 2025, Sanofi initiated a study evaluating the safety and immunogenicity of its investigational pneumococcal conjugate vaccine, SP0202, when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers, with PREVNAR 13 as the comparator.
• In March 2025, Merck announced that the European Commission approved PCV21 (CAPVAXIVE) for the prevention of IPD and pneumonia caused by 21 Streptococcus pneumoniae serotypes in adults aged 18 years and older. The approval was supported by safety and immunogenicity data from the Phase III STRIDE clinical program, with CAPVAXIVE specifically designed to target the serotypes responsible for most adult IPD cases.

Drug Class Insights

Invasive Pneumococcal Disease (IPD) Market Outlook

The IPD market is witnessing a steady transition driven primarily by the continued evolution and expansion of PCV coverage, with a strong emphasis on broader serotype protection and improved prevention of adult and pediatric disease burden. The market is currently dominated by established and next-generation vaccines, including PCV13 (PREVNAR13), PCV15 (VAXNEUVANCE), PCV20 (PREVNAR/APEXXNAR), and PCV21 (CAPVAXIVE), which are reshaping immunization strategies by expanding serotype coverage and addressing residual disease caused by non-vaccine serotypes. In addition, emerging pipeline candidates such as SP0202, PF-07872412 (25vPnC), and GSK5459248 further highlight ongoing efforts to enhance breadth of protection and improve long-term control of pneumococcal infections.

With increased focus on higher-valency vaccines and broader population coverage, the IPD landscape is shifting toward next-generation preventive strategies to reduce residual invasive disease, particularly in high-risk pediatric, elderly, and immunocompromised populations. The introduction and adoption of expanded-valency PCVs are expected to significantly influence immunization policies, competitive positioning, and global vaccination programs, particularly in regions with high disease burden and evolving serotype distribution.

Overall, the continued advancement of higher-valency pneumococcal vaccines, coupled with ongoing pipeline innovation and the growing global emphasis on preventing bacterial infections, is expected to drive sustained growth in the IPD market. This evolving landscape presents significant commercial opportunities for both established vaccine manufacturers and emerging developers focused on next-generation pneumococcal prevention strategies.

• According to the estimates, the United States accounted for the largest share of the Invasive Pneumococcal Disease (IPD) market among the major markets during the study period.
• The IPD market is evolving as prevention strategies shift from traditional pneumococcal vaccines toward broader serotype coverage and next-generation conjugate vaccines, with emerging candidates such as higher-valent PCVs and protein-based vaccines driving efforts to improve protection against circulating and non-vaccine serotypes and reduce invasive disease burden.
• Regional market dynamics show the United States leading in vaccine uptake, surveillance, and clinical research, while Europe and Japan are increasingly focused on immunization programs and expanding adoption of pneumococcal vaccination, driven by rising awareness of the invasive disease burden, ageing populations, and strengthened public health initiatives.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Invasive Pneumococcal Disease (IPD) (2022-2036 Forecast)

The IPD treatment and prevention landscape comprises vaccines (PCVs and PPSVs), antibiotic therapy, adjunctive anti-inflammatory therapy, supportive care therapies and emerging and preventive biologics, each targeting different stages of Streptococcus pneumoniae infection, disease progression, and host immune response.

Vaccines (PCVs and PPSVs): Pneumococcal conjugate vaccines (e.g., PCV13, PCV15, PCV20, and higher-valent candidates) and polysaccharide vaccines (PPSV23) work by inducing serotype-specific antibody responses against pneumococcal capsular polysaccharides, enhancing opsonophagocytic killing and preventing colonisation and invasive disease.

Overall, vaccines and antibiotics currently dominate the IPD management and prevention landscape, while emerging, broader-spectrum immunization strategies and novel biologics are shaping future innovation aimed at improving coverage, reducing the impact of resistance, and lowering the burden of invasive disease.

Invasive Pneumococcal Disease (IPD) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the IPD market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Established pneumococcal conjugate vaccines, such as PCV13 (PREVNAR 13) and PCV15 (VAXNEUVANCE), have demonstrated clinical efficacy, broad guideline inclusion, and widespread use in pediatric and adult immunization programs. Newer higher-valent vaccines, including PCV20 (PREVNAR/APEXXNAR) and PCV21 (CAPVAXIVE), are anticipated to witness significant market share owing to their expanded serotype coverage and potential to address residual IPD burden. Their adoption is expected to be driven by evolving vaccination recommendations, growing awareness of serotype replacement, and the need for broader protection across at-risk populations.

Market Access and Reimbursement of Invasive Pneumococcal Disease (IPD)

The report further provides detailed insights on country-wise accessibility and reimbursement scenarios, the cost-effectiveness of approved therapies, programs that make accessibility easier and out-of-pocket costs more affordable, patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects a drug's market access. Often, the decision to reimburse comes down to the drug's price relative to the benefit it provides to treated patients. To reduce the healthcare burden of high-cost therapies, many payers and other industry stakeholders are considering payment models.

Invasive Pneumococcal Disease (IPD) Therapies Price Scenario & Trends

Pricing and analogue assessment of IPD therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Invasive Pneumococcal Disease (IPD)

To keep up with IPD market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the IPD emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in IPD, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of Mississippi Medical Center, University of Bologna, and Teikyo University School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging IPD therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in IPD.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Invasive Pneumococcal Disease (IPD), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of IPD, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the IPD market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM IPD market.

Report Insights

• Invasive Pneumococcal Disease (IPD)Patient Population Forecast
• Invasive Pneumococcal Disease (IPD)Therapeutics Market Size
• Invasive Pneumococcal Disease (IPD)Pipeline Analysis
• Invasive Pneumococcal Disease (IPD)Market Size and Trends
• Invasive Pneumococcal Disease (IPD)Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Invasive Pneumococcal Disease (IPD)Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Invasive Pneumococcal Disease (IPD)Treatment Addressable Market (TAM)
• Invasive Pneumococcal Disease (IPD)Competitive Landscape
• Invasive Pneumococcal Disease (IPD)Major Companies Insights
• Invasive Pneumococcal Disease (IPD)Price Trends and Analogue Assessment
• Invasive Pneumococcal Disease (IPD)Therapies Drug Adoption/Uptake
• Invasive Pneumococcal Disease (IPD)Therapies Peak Patient Share analysis

Report Assessment

• Invasive Pneumococcal Disease (IPD)Current Treatment Practices
• Invasive Pneumococcal Disease (IPD)Unmet Needs
• Invasive Pneumococcal Disease (IPD)Clinical Development Analysis
• Invasive Pneumococcal Disease (IPD)Emerging Drugs Product Profiles
• Invasive Pneumococcal Disease (IPD)Market Attractiveness
• Invasive Pneumococcal Disease (IPD)Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Invasive Pneumococcal Disease (IPD) market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Invasive Pneumococcal Disease (IPD)?
• What are the disease risks, burdens, and unmet needs of Invasive Pneumococcal Disease (IPD)? What will be the growth opportunities across the 7MM concerning the patient population with Invasive Pneumococcal Disease (IPD)?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Invasive Pneumococcal Disease (IPD)? What are the current guidelines for treating Invasive Pneumococcal Disease (IPD) in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Invasive Pneumococcal Disease (IPD) market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Invasive Pneumococcal Disease (IPD) Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of IPD By Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of IPD By Therapies in the 7MM, in 2036

7. Disease Background and Overview of Invasive Pneumococcal Disease (IPD)

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Causes
• 7.4. Risk factors
• 7.5. Pathophysiology
• 7.6. Diagnosis
  • 7.6.1. Differential Diagnosis
  • 7.6.2. Diagnostic Algorithm

8. Treatment

• 8.1. Algorithm for the Treatment
• 8.2. Guidelines for the Treatment

9. Epidemiology and Patient Population of Invasive Pneumococcal Disease (IPD)

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Total Diagnosed Prevalent Cases of IPD in the 7MM
• 9.4. The United States
  • 9.4.1. Total Incident Cases of Invasive Pneumococcal Disease (IPD) in United States
  • 9.4.2. Age-specific Incident Cases of Invasive Pneumococcal Disease (IPD) in United States
  • 9.4.3. Gender-specific Incident Cases of Invasive Pneumococcal Disease (IPD) in United States
  • 9.4.4. Treatable Cases of Invasive Pneumococcal Disease (IPD) in United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Incident Cases of Invasive Pneumococcal Disease (IPD) in EU4 and the UK
  • 9.5.2. Age-specific Incident Cases of Invasive Pneumococcal Disease (IPD) in EU4 and the UK
  • 9.5.3. Gender-specific Incident Cases of Invasive Pneumococcal Disease (IPD) in EU4 and the UK
  • 9.5.4. Treatable Cases of Invasive Pneumococcal Disease (IPD) in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Incident Cases of Invasive Pneumococcal Disease (IPD) in Japan
  • 9.6.2. Age-specific Incident Cases of Invasive Pneumococcal Disease (IPD) in Japan
  • 9.6.3. Gender-specific Incident Cases of Invasive Pneumococcal Disease (IPD) in Japan
  • 9.6.5. Treatable Cases of Invasive Pneumococcal Disease (IPD) in Japan

10. Patient Journey of Invasive Pneumococcal Disease (IPD)

11. Marketed Drugs

• 11.1. Marketed Competitive Landscape of Invasive Pneumococcal Disease (IPD)
• 11.2. PCV20 (PREVNAR/APEXXNAR): Pfizer
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views
• 11.3. PCV21 (CAPVAXIVE): Merck
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst's Views

. Note: List to be continued in the report

12. Emerging Drugs

• 12.1. Emerging Competitive Landscape of Invasive Pneumococcal Disease (IPD)
• 12.2. SP0202: Sanofi/ SK Bioscience
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst's Views
• 12.3. PF-07872412 (25vPnC): Pfizer
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Analyst's Views

. Note: List to be continued in the report

13. Invasive Pneumococcal Disease (IPD): 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of Invasive Pneumococcal Disease (IPD)
• 13.3. Conjoint Analysis of Invasive Pneumococcal Disease (IPD)
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions
  • 13.4.2. Pricing Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of Invasive Pneumococcal Disease (IPD) in the 7MM
• 13.6. Total Market Size of Invasive Pneumococcal Disease (IPD) by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of Invasive Pneumococcal Disease (IPD) in the United States
  • 13.7.2. Total Market Size of Invasive Pneumococcal Disease (IPD) by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of Invasive Pneumococcal Disease (IPD) in EU4 and the UK
  • 13.8.2. Total Market Size of Invasive Pneumococcal Disease (IPD) by Therapies in EU4 and the UK
• 13.9. Japan
  • 13.9.1. Total Market Size of Invasive Pneumococcal Disease (IPD) in Japan
  • 13.9.2. Total Market Size of Invasive Pneumococcal Disease (IPD) by Therapies in Japan

14. Unmet Needs of Invasive Pneumococcal Disease (IPD)

15. SWOT Analysis of Invasive Pneumococcal Disease (IPD)

16. KOL Views of Invasive Pneumococcal Disease (IPD)

17. Market Access and Reimbursement of Invasive Pneumococcal Disease (IPD)

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of Invasive Pneumococcal Disease (IPD) Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight